Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Amikacin Amoxicillin Amoxicillin/clavulanic acid (amoxicillin + clavulanic acid) Ampicillin Benzathine benzylpenicillin Benzylpenicillin Cefalexin Cefazolin Chloramphenicol Clindamycin Cloxacillin Doxycycline Gentamicin Metronidazole Nitrofurantoin Phenoxymethylpenicillin (penicillin V) Procaine benzylpenicillin Spectinomycin Sulfamethoxazole/trimethoprim (sulfamethoxazole + trimethoprim) Trimethoprim
This important area focuses on structure, bonding, and the physical properties of materials. In practice, solid state inorganic chemistry uses techniques such as crystallography to gain an understanding of the properties that result from collective interactions between the subunits of the solid. Included in solid state chemistry are metals and their alloys or intermetallic derivatives. Related fields are condensed matter physics, mineralogy, and materials science.
== External links == Prof. Matthias Tschöp (16 May 2012). Medicine: Prof. Matthias Tschöp. Alexander von Humboldt Foundation. Prof. Matthias Tschöp, Chair of Metabolic Diseases, TUM School of Medicine
D-amino-acid transaminase (EC 2.6.1.21) is an enzyme originally characterised from bacteria that catalyzes several reversible chemical reactions that interconvert specific D-amino acids and α-ketoglutaric acid with the corresponding α-keto acid and D-glutamic acid. For example, it can use D-alanine as a substrate:
Sources: en.wikipedia.org
As part of the discovery phase, Valve received a number of documents in Korean, which a new intern at Valve was able to translate, purporting that Vivendi had directed the destruction of evidence for the case. When shown to the court, the judge took action to block Vivendi's countersuits, turning the case in Valve's direction. On November 29, 2004, Judge Thomas Samuel Zilly of the U.S. District Court for the Western District of Washington ruled in favor of Valve. The ruling stated that Vivendi Universal and its affiliates (including Sierra) were not authorized to distribute Valve games, either directly or indirectly, through cyber cafés to end users for pay-to-play activities pursuant to the parties' publishing agreement. In addition, Judge Zilly ruled that Valve could recover copyright damages for infringements without regard to the publishing agreement's limitation of liability clause. Valve posted on the Steam website that the companies had come to a settlement in court on April 29, 2005. As a result of the trial, the arbitrator also awarded Valve $2,391,932.
Growth hormone secretagogues or GH secretagogues (GHSs) are a class of drugs which act as secretagogues (i.e., induce the secretion) of growth hormone (GH). They include agonists of the ghrelin/growth hormone secretagogue receptor (GHSR), such as ghrelin (lenomorelin), pralmorelin (GHRP-2), GHRP-6, examorelin (hexarelin), ipamorelin, and ibutamoren (MK-677), and agonists of the growth hormone-releasing hormone receptor (GHRHR), such as growth hormone-releasing hormone (GHRH, somatorelin), CJC-1295, sermorelin, and tesamorelin. Many of them also induce the secretion of insulin-like growth factor 1 (IGF-1), as well as of other hypothalamic-pituitary hormones such as prolactin and cortisol. The main clinical application of these agents is the treatment of growth hormone deficiency.
Traditionally, the peppers are moved to a closed smoking chamber and spread on racks. Wood is put in a firebox, and the smoke enters the sealed chamber. Every few hours, the jalapeños are stirred to mix in the smoke. They are smoked for several days until most of the moisture is removed. The moisture within the red jalapeño peppers slightly decreases from 88% to 81% during the first three days, but by the end of the drying process, the moisture level reaches a final value of 6%. In the end, the chipotles are dried and shriveled like prunes or raisins. The underlying heat of the jalapeños combines with the taste of smoke, forming a flavor distinctive to chipotle peppers. Typically, ten pounds of jalapeños make one pound of chipotles after thoroughly drying. In recent years, some commercial producers have begun using large gas dryers and artificial smoke flavoring, which expedites the drying process but produces a less flavorful chipotle. Other chilis can be smoked and dried for chipotle pepper, such as the bell or serrano variety, but smoked red jalapeños are most commonly used.
== National laws, regulations, and management == Laws governing aquaculture practices vary greatly by country and are often not closely regulated or easily traceable. In the United States, land-based and nearshore aquaculture is regulated at the federal and state levels; no national laws govern offshore aquaculture in U.S. exclusive economic zone waters. In June 2011, the Department of Commerce and National Oceanic and Atmospheric Administration released national aquaculture policies to address this issue and "to meet the growing demand for healthy seafood, to create jobs in coastal communities, and restore vital ecosystems." Large aquaculture facilities (i.e. those producing 20,000 pounds (9,100 kg) per year) which discharge wastewater are required to obtain permits pursuant to the Clean Water Act. Facilities that produce at least 100,000 pounds (45,000 kg) of fish, molluscs or crustaceans a year are subject to specific national discharge standards. Other permitted facilities are subject to effluent limitations that are developed on a case-by-case basis.
=== Diplomatic espionage === French diplomat Talleyrand served as a source of intelligence for the Coalition powers against Napoleon. At the Congress of Erfurt in September–October 1808, Talleyrand secretly counseled Tsar Alexander. Alexander's attitude towards Napoleon was one of apprehensive opposition. Talleyrand believed Napoleon would eventually destroy the empire he had worked to build across multiple rulers. After his resignation in 1807 from the ministry, Talleyrand began to accept bribes from hostile powers (mainly Austria, but also Russia), to betray Napoleon's secrets. Various agents of Napoleon were known such as Madame d'Oettlinger.
Sources: en.wikipedia.org
=== MeSH D12.644.641 – peptides, cyclic === MeSH D12.644.641.040 – alamethicin MeSH D12.644.641.050 – amanitins MeSH D12.644.641.075 – bacitracin MeSH D12.644.641.142 – capreomycin sulfate MeSH D12.644.641.235 – cyclosporins MeSH D12.644.641.235.300 – cyclosporine MeSH D12.644.641.243 – cyclotides MeSH D12.644.641.252 – dactinomycin MeSH D12.644.641.270 – daptomycin MeSH D12.644.641.297 – depsipeptides MeSH D12.644.641.297.500 – valinomycin MeSH D12.644.641.325 – echinomycin MeSH D12.644.641.380 – ferrichrome MeSH D12.644.641.515 – mycobacillin MeSH D12.644.641.548 – nanotubes, peptide MeSH D12.644.641.582 – nisin MeSH D12.644.641.650 – octreotide MeSH D12.644.641.735 – phalloidine MeSH D12.644.641.780 – polymyxins MeSH D12.644.641.780.110 – colistin MeSH D12.644.641.780.750 – polymyxin b MeSH D12.644.641.802 – streptogramins MeSH D12.644.641.802.249 – mikamycin MeSH D12.644.641.802.374 – pristinamycin MeSH D12.644.641.802.500 – streptogramin group a MeSH D12.644.641.802.500.500 – streptogramin a MeSH D12.644.641.802.750 – streptogramin group b MeSH D12.644.641.802.750.500 – streptogramin b MeSH D12.644.641.802.812 – vernamycin b MeSH D12.644.641.802.875 – virginiamycin MeSH D12.644.641.802.875.500 – streptogramin a MeSH D12.644.641.825 – thiostrepton MeSH D12.644.641.875 – viomycin MeSH D12.644.641.875.250 – enviomycin
Salicylic acid (SA), a phytohormone, was initially derived from willow bark and has since been identified in many species. It is an important player in plant immunity, although its role is still not fully understood by scientists. They are involved in disease and immunity responses in plant and animal tissues. They have salicylic acid binding proteins (SABPs) that have shown to affect multiple animal tissues. The first discovered medicinal properties of the isolated compound was involved in pain and fever management. They also play an active role in the suppression of cell proliferation. They have the ability to induce death in lymphoblastic leukemia and other human cancer cells. One of the most common drugs derived from salicylates is aspirin, also known as acetylsalicylic acid, with anti-inflammatory and anti-pyretic properties.
The drug's primary indication was the treatment of penicillin-resistant Staphylococcus aureus. The drug was given to a patient who had developed a severe infection on his foot after surgery which had been unresponsive to multiple antibiotics. The surgical staff had recommended amputation or the use of the new antibiotic. His answer was, "Anything that might save my foot". Due to the spread of the bacteria, a high dosage of the antibiotic 05865 was recommended, 100 mg every eight hours, over five days. After the first day, the heat was decreasing, his white cell count was dropping, and the exudate of his wound was less. During the next seven days, the staphylococci disappeared from the wound, and his foot was free from any sign of infection. Two months later, he left the hospital with an intact foot. The drug was fast-tracked for approval by the Food and Drug Administration due to the clinical need for effective anti-staphylococcal agents and an observed lack of resistance development in serial passage in culture media with the drug. The origins of the generic name vancomycin differ; some sources state the name was is linked to the term "vanquish", with others stating it came from the Latin word "vanesco", which means to vanish or disappear. In 1958, Eli Lilly began marketing vancomycin hydrochloride under the trade name Vancocin. Vancomycin never became the first-line treatment for S. aureus for several reasons:
=== Grey market use === Suvomipic has attracted an unusual amount of attention for an investigational drug, such as in the r/Tressless subreddit about hair loss on Reddit. A large group of r/Tressless members, having believed that JXL069 is suvomipic, are known to have sourced JXL069 from China in 2025 in an effort to treat their hair loss. This included sending a sample to an analytical testing lab to confirm the compound's authenticity. Pelage Pharmaceuticals says that it does not endorse such use and has explicitly stated that suvomipic is not JXL069. Suvomipic is also said to not be JXL082. In July 2026, the INNTooltip International Nonproprietary Name of suvomipic was published and revealed that suvomipic is in fact JXL069.
By that time, BMS had already withdrawn the drug from the market in Europe, Australia, New Zealand, and Canada. In August 2020, Teva Pharmaceuticals placed nefazodone in shortage due to a shortage of a raw ingredient. On December 20, 2021, nefazodone was again made available in all strengths.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.